MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.12
-0.02
-0.25%
After Hours: 8.16 +0.04 +0.49% 19:30 06/11 EDT
OPEN
8.10
PREV CLOSE
8.14
HIGH
8.20
LOW
7.97
VOLUME
496.17K
TURNOVER
--
52 WEEK HIGH
10.25
52 WEEK LOW
4.201
MARKET CAP
167.52M
P/E (TTM)
-1.9475
1D
5D
1M
3M
1Y
5Y
SCYNEXIS to Present at the BIO Digital International Convention 2021
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCY...
GlobeNewswire · 2d ago
Scynexis' Brexafemme For Vaginal Yeast Infections Secures 10 Years Regulatory Exclusivity
Benzinga · 4d ago
Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Scynexis (SCYX) announces that the FDA has granted Brexafemme (ibrexafungerp tablets), five years of exclusivity extension under the Generating Antibiotic Incentives Now ((GAIN)) Act.This grant will be added to any
Seekingalpha · 4d ago
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jun. 9, 2021: EA, WISH, SCYX, COIN, CLVS
Today's 5 Stock Ideas Electronic Arts (EA) - A play on the upcoming video game conference, E3. The event runs from Jun. 12 to Jun. 15. Benzinga will be hosting a preview of E3 on its YouTube
Benzinga · 4d ago
BRIEF-Scynexis Confirms That Brexafemme® (Ibrexafungerp Tablets) Qualifies For 10 Years Of Regulatory Exclusivity For Vaginal Yeast Infections
reuters.com · 4d ago
SCYNEXIS Announces FDA Granted BREXAFEMME Five Years Of Exclusivity Under GAIN Act
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that the U.S. Food and Drug
Benzinga · 4d ago
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
BREXAFEMME® (ibrexafungerp tablets), for oral use A novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total ...
GlobeNewswire · 4d ago
SCYNEXIS Receives Exclusivity Extension From US FDA for Brexafemme in Vaginal Yeast Infections Treatment
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCYX. Analyze the recent business situations of SCYNEXIS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCYX stock price target is 25.44 with a high estimate of 35.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 16.70M
% Owned: 80.97%
Shares Outstanding: 20.63M
TypeInstitutionsShares
Increased
18
859.71K
New
11
994.51K
Decreased
3
176.82K
Sold Out
10
4.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Director
Pamela Kirby
President/Chief Executive Officer/Director
Marco Taglietti
Chief Financial Officer
Eric Francois
Vice President/Director of Sales/Director of Marketing
Jim Maffezzoli
Vice President
Nkechi Azie
General Counsel
Scott Sukenick
Other
David Angulo
Other
Christine Coyne
Director
Armando Anido
Director
Laurent Arthaud
Director
Steven Gilman
Director
Ann Hanham
Director
David Hastings
Director
Clarence Machado
Director
Patrick Langlois
Director
Guy Macdonald
Director
Jean-Yves Nothias
Director
Philippe Tinmouth
No Data
About SCYX
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.